MegaMOST - A multicenter, open-label, biology driven, Phase II study evaluating the activity of anti-cancer treatments targeting tumor molecular alterations/characteristics in advanced / metastatic tumors

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510567-35-00

Acronym

ET19-073

Enrollment

455

Registered

2024-09-13

Start date

2020-06-10

Completion date

Unknown

Last updated

2026-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced / metastatic cancers

Brief summary

Progression free rate after 3 months of treatment (3M-PFR). (12 weeks)

Detailed description

Objective response rate after 3 months of treatment (3M-ORR), Duration of Response (DoR), Progression Free Survival (PFS), Overall survival (OS), Percentage of long-term responders (> 6 months)

Interventions

DRUGHDM201

DRUGALECTINIB

DRUGRIBOCICLIB

DRUGTRAMETINIB

DRUGDABRAFENIB

DRUGREGORAFENIB

DRUGAVAPRITINIB

DRUGCABOZANTINIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression free rate after 3 months of treatment (3M-PFR). (12 weeks)	—

Secondary

Measure	Time frame
Objective response rate after 3 months of treatment (3M-ORR), Duration of Response (DoR), Progression Free Survival (PFS), Overall survival (OS), Percentage of long-term responders (> 6 months)	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026